INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

Giuseppe Privitera  ¹     Elena Melita  ²     Lucia Monastero  ²     Maria Chiara Agnitelli  ²     Federica Di Vincenzo  ²     Marcello Fiorani  ²     Pierluigi Puca  ²     Elisa Schiavoni  ³     Valeria Amatucci  ³     Daniele Napolitano  ³     Martina Strazzeri  ³     Laura Turchini  ³     Franco Scaldaferri  ³     Daniela Pugliese  ^4    
1 Università degli Studi di Milano, Milan, Italy
² Università Cattolica del Sacro Cuore, Rome, Italy
³ Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
⁴ Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)